Impact of COVID-19 Related Policy Changes on Buprenorphine Dispensing in Texas.
Impact of COVID-19 Related Policy Changes on Buprenorphine Dispensing in Texas.
复制标题
DOI：
10.1097/adm.0000000000000756
复制
发表时间：
2020-12
影响因子：
5.5
通讯作者：
Shen C
中科院分区：
文献类型：
--
作者：
Thornton JD;Varisco TJ;Bapat SS;Downs CG;Shen C
测量德克萨斯州COVID-19（SARS-CoV-2）大流行早期接受丁丙诺啡治疗的患者和丁丙诺啡处方者的每日人数变化。计算了2019年11月4日至2020年5月12日期间每个工作日的填充患者数量和处方丁丙诺啡的提供者数量。使用自回归、中断时间序列回归，将2020年3月2日至2020年5月12日期间每日患者和处方者的变化建模为与基线期相比的斜率变化。与基线相比，COVID-19期间每日丁丙诺啡处方（β = −1.75，95%CI = −5.8-2.34）和处方者（β = −0.32，95%CI = −1.47-0.82）的变化率下降不显著。尽管2020年3月和4月期间美国中南部的门诊护理利用率下降了57%，但德克萨斯州与丁丙诺啡相关的医疗服务利用率仍然强劲。随着COVID-19大流行的持续发展，保护丁丙诺啡的获得需要临床医生和政策制定者的大力努力。虽然目前的结果很有希望，但研究人员必须继续监测和探索COVID-19对物质使用障碍治疗的临床和人文影响。
To measure the change in the daily number of patients receiving buprenorphine and buprenorphine prescribers during the early phase of the COVID-19 (SARS-CoV-2) pandemic in Texas. Counts of the number of patients filling and number of providers prescribing buprenorphine were calculated for each weekday between November 4, 2019 and May 12, 2020. The change in daily patients and prescribers between March 2, 2020 and May 12, 2020, was modeled as a change in slope compared to the baseline period using autoregressive, interrupted time series regression. The rate of change of daily buprenorphine prescriptions (β = −1.75, 95% CI = −5.8–2.34) and prescribers (β = −0.32, 95% CI = −1.47–0.82) declined insignificantly during the COVID-19 period compared to the baseline. Despite a 57% decline in ambulatory care utilization in the south-central US during March and April of 2020, health services utilization related to buprenorphine in Texas remained robust. Protecting access to buprenorphine as the COVID-19 pandemic continues to unfold will require intensive efforts from clinicians and policy makers alike. While the presented results are promising, researchers must continue monitoring and exploring the clinical and humanistic impact of COVID-19 on the treatment of substance use disorders.